Physician profile
Faisal Bukhari
NPI 1376545509
$6,162.48
in general payments reported to CMS, 2019-2025
40 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $883 · 2021: $1,962 · 2022: $855 · 2023: $781 · 2024: $522 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.28 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $580.14 | 2019-2022 | |
| Astellas Pharma US INC | $541.42 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $539.87 | 2019-2022 | |
| Abbott Laboratories | $306.25 | 2021-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $304.74 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $302.80 | 2019-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $300.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $291.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $286.10 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.37 | 2020-2023 | Xifaxan |
| Amgen INC. | $251.03 | 2019-2023 | Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $205.95 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $193.83 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $190.42 | 2020-2021 | |
| Biogen, INC. | $165.37 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Bukhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.